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Background
Host defense peptides (HDPs) are naturally occurring
molecules found in most eukaryotic species, in which
they play a significant role in the first line of defense
against pathogens. Several HDPs have shown to possess
anticancer activity. Structure-anti-cancer activity rela-
tionship studies on the HDP bovine lactoferricin has
resulted in the design of a short oncolytic 9-mer pep-
tide, LTX-315. Mode of action studies indicate that
LTX-315 induces release of tumour antigens and potent
DAMPS by distortion of intracellular organelles in can-
cer cells. Animal studies have demonstrated that intratu-
moural (i.t.) treatment of several different types of
syngeneic murine tumours with LTX-315 resulted in
complete tumor regression and tumor specific immune
responses. In the present study, we examined the poten-
tial synergistic effects of using LTX-315 in combination
with anti-PD1 or anti-CTLA4 blockade.
Methods
C57BL/6 mice with MCA205 sarcomas were first treated
i.p. with either anti-PD1 Ab or anti-CTLA4 Ab followed
by intra-tumoural administration of LTX-315.
Results
Intratumoural (i.t.) administration of LTX-315 resulted
in a synergistic antitumour effect when combined with
i.p. administration of anti-PD1 or anti-CTLA4 compared
to the effect of either the immune checkpoint inhibitors
or LTX-315 alone. A synergistic effect was also achieved
against distant non-treated lesions with local administra-
tion of anti-CTLA4 Ab (s.c.) and LTX-315 (i.t.) in
combination.
Conclusions
Our results demonstrate that LTX-315 in combination
with anti-CTLA4 or anti-PD1 results in a synergistic
antitumour effect in vivo. Thus, a combination therapy
with the oncolytic peptide LTX-315 that mounts specific
T cell responses against released tumour antigens and
immune checkpoint inhibitors that can augment the
tumour specific T cell responses represent a promising
combination strategy in future cancer therapy. One
Phase I study with LTX-315 is completed and a 2nd is
ongoing. Combination studies together with immune
checkpoint inhibitors are planned.
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